Kideok Jin

Kideok Jin

Education

  • PhD, SUNY Upstate Medical University

Previous Positions & Appointments

  • Research Associate, Johns Hopkins University
  • Postdoctoral Fellow, Johns Hopkins University

Courses Taught at ACPHS

  • Molecular Biology (undergraduate)
  • Pharmaceutical Sciences Research Experience (undergraduate)
  • Thesis I & II (undergraduate)
  • Pharmacology & Molecular Genetics of Cancer (graduate)
  • Pharmaceutical Analytical Techniques (undergraduate)
  • Pharmaceutical Sciences Research Seminar

Academic Research & Interests

About 70% of estrogen receptor (ER) positive breast cancers have significantly reduced the risk of invasive breast cancer by various endocrine therapies. Despite the relative safety and significant anti-neoplastic and chemopreventive activities of tamoxifen and aromatase inhibitors, many initially responsive breast tumors develop resistance and ultimately recur.

My current research is to investigate the secretome leading to the endocrine resistance in crosstalk between endocrine resistant breast cancer and tumor microenvironment.

The long-term mission of my laboratory is to understand the steps of the endocrine resistant process to develop therapeutic approaches to prevent and treat endocrine resistant breast cancer effectively. The ultimate goal of my research is to bring therapies into the clinic that will improve the survival of metastatic breast cancer patients.

Learn More About Dr. Jin

  • NIH grant R15 CA271221 (PI)
  • NIH grant R15 CA287244 (Collaborator)

  • ACPHS Research Committee
  • Faculty Senate
  • Institutional Biosafety Committee (IBC)
  • MS Pharmaceutical Sciences Admissions Committee

Pandithar S, Galke D, Akume A, Belyakov A, Lomonaco D, Guerra AA, Park J, Reff O, Jin K. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast. Mol Biol Rep. 2024 Feb 23;51(1):331. doi: 10.1007/s11033-023-09119-4. PubMed PMID: 38393465; PubMed Central PMCID: PMC10891235.

Blakely B, Shin S, Jin K. Overview of the therapeutic strategies for ER positive breast cancer. Biochem Pharmacol. 2023 Jun;212:115552. doi: 10.1016/j.bcp.2023.115552. Epub 2023 Apr 15. Review. PubMed PMID: 37068524; PubMed Central PMCID: PMC10394654.

Smrekar K, Belyakov A, Jin K. Crosstalk between triple negative breast cancer and microenvironment. Oncotarget. 2023 Mar 31;14:284-293. doi: 10.18632/oncotarget.28397. Review. PubMed PMID: 36999995; PubMed Central PMCID: PMC10064880.

Malone MK, Smrekar K, Park S, Blakely B, Walter A, Nasta N, Park J, Considine M, Danilova LV, Pandey NB, Fertig EJ, Popel AS, Jin K. Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy. Cancer Biol Ther. 2020 Jun 2;21(6):560-569. doi: 10.1080/15384047.2020.1739484. Epub 2020 Mar 26. PubMed PMID: 32213106; PubMed Central PMCID: PMC7515526.

Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Research 2018 Jun 14;20(1):54. (corresponding author).

Jin K, Targeting CCL5 signaling pathway in endocrine resistant breast cancer therapy, April 25-30, Chicago, IL 2025.

Jin K, The HOXB7 protein promotes breast cancer cell growth through activation of the CCL5/CCR5 pathway in the crosstalk of adipocyte, April 5-10, Sandiego, CA 2024.

Jin K, The role of CXCL1 in crosstalk between breast cancer cells with ESR1 mutations and lymphatic endothelial cells, April 14-19, Orlando, FL, 2023.

Jin K, Reparixin, CXCR1/2 inhibitor in combination with CDK4/6 inhibitors attenuates endocrine resistant breast cancer growth and metastasis, April 8-13, New Orleans, LA, 2022 (Invited talk)

Jin K, HOXB7, a key transcriptional regulator in triple negative breast cancer progression, Virtual Meeting, April 10-15, 2021

Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. AACR Annual Meeting, Chicago IL, April 14-18, 2018.

Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. SUNY Albany, CRC Research Seminar (invited talk).

Jin K. Crosstalk between Stromal Components and Endocrine Resistant Breast Cancer via Secreted Factors Enhances Tumor Growth and Metastasis. 8th Annual Research Forum, Albany College of Pharmacy and Health Sciences, Albany NY, January 27, 2018 (invited talk).

  • 2020 Scholarship of Discovery Grant Award
  • 2021 Scholarship of Discovery Grant Award
  • 2022 Rudolph and Dorothy Blythe Research Award
  • Preclinical Catalyst Program Reviewer, Breast Cancer Now (UK)

Active Member of the American Association for Cancer Research (AACR)